Oxford Pharmascience is led by an industry-leading management team with a strong track record in global healthcare and experience in life sciences, chemistry, pharmaceutical technologies, and clinical development.
Marcelo Bravo is a founder of Oxford Pharmascience and an entrepreneur with a background in chemistry and chemical engineering and international experience with blue-chip companies. Marcelo spent 16 years in R&D with The Procter & Gamble Company and subsequently spent 3 years in corporate development with Boots (now Boots Alliance Plc). After this he became an entrepreneur and most recently was CEO and Board director of Oxford Advanced Surfaces Group Plc, a company he led from inception as a spin-out from Oxford University which is now quoted on the AIM market. Marcelo has extensive experience in developing, launching and growing new products and businesses across a range of both geographic and product markets. Marcelo holds a B.A. in Chemistry from the College of Wooster, USA and a B.Sc. in Chemical Engineering from Case Western Reserve University, USA and an M.Sc in Management from the London Business School.
Dr Liz King has comprehensive background in the pharmaceutical industry and in-depth experience of pharmaceutical drug development within the EU and US from the discovery phase through to registration and life-cycle management. Liz has managed multi-functional, international teams, defined drug development strategies, managed the implementation of drug development plans, led due diligence activities, submitted orphan drug applications, managed strategic alliances, participated in FDA and EU regulatory agency meetings and overseen global licence conformance programmes. Liz also has experience of pharmaceutical sciences, technology transfer and business development. Liz has a PhD from the University of Cambridge on polymer science and has worked at Pfizer, Shire Pharmaceuticals, ProStrakan, Mitovie and Pharmalink Consulting.
Sheryl Caswell has more than 15 years of experience developing and executing global clinical programs for novel and first-in-class products from Phase I through Phase IV, with particular experience in early phase clinical development. Most recently as Clinical Programme Lead at Biogen Idec Ltd, she led the clinical programs of two of the company's product candidates in neurology. Prior to that she served as Programme Director and Director of Clinical Research for Plethora Solutions where she led the clinical function as well as had overall clinical development responsibility for early phase products.
Ann Taylor-Hutchinson has over 20 years' experience in the Pharmaceutical Industry from new product development through to Quality Control, including project management, regulatory submissions and product release. A graduate Chemist, Ann has worked for Boots in both Contract Manufacturing and R&D, Reckitt Benckiser, Innovata Biomed and most recently Molecular Profiles within the Pharmaceutical Development Services.